Global Market Report

Clinical Oncology Next Generation Sequencing (NGS) Market Report 2019-2029

Along with revenue prediction for the overall world market, there are 4 segmentations of the Clinical Oncology Next Generation Sequencing (NGS) market, with forecasts for 4 Components, 8 Technologies, 6 Applications and 4 End Users, each forecasted at a global and regional level.

SKU: PHA0488 Category: Tags: , , , , Code: PHA0488Pages: 167
Clear
← Back to category Next Generation Technologies

Description

Clinical Oncology Next Generation Sequencing (NGS) , our new study reveals trends, R&D progress, and predicted revenues
Where is the Clinical Oncology Next Generation Sequencing (NGS) market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2029, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead
Our 242-page report provides 35 tables, 190 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Clinical Oncology Next Generation Sequencing (NGS) market. See how to exploit the opportunities.

Forecasts to 2029 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2029, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Component profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are 4 segmentations of the Clinical Oncology Next Generation Sequencing (NGS) market, with forecasts for 4 Components, 8 Technologies, 6 Applications and 4 End Users, each forecasted at a global and regional level.

Global Clinical Oncology Next Generation Sequencing (NGS) Market by Component
• Sequencing Platform
• Sequencing Products
• End Users and Reagents
• Services

Global Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
• Microarray
• Ion Semiconductor Sequencing
• Pyro-Sequencing
• Synthesis Sequencing (SBS)
• Real Time Sequencing (SMRT)
• Ligation Sequencing
• Reversible Dye Termination Sequencing
• Nano -Pore Sequencing
• Others

Global Clinical Oncology Next Generation Sequencing (NGS) Market by Application
• Whole Tumor Genome Sequencing
• Whole Tumor Exome Sequencing
• Targeted Tumor Genome Profiling
• Tumor Transcriptome Sequencing
• Tumor -normal Comparisons
• Others

Global Clinical Oncology Next Generation Sequencing (NGS) Market by End User
• Hospital Laboratories
• Clinical Research Organizations
• Diagnostic Laboratories
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 7 regional and 17 leading national markets:

• North America:
• US
• Canada

• Latin America:
• Brazil
• Mexico
• Rest of Latin America

• Western Europe:
• Germany
• The UK
• Italy
• France
• Spain
• Nordic
• Benelux
• Rest of Western Europe

• Eastern Europe:
• Russia
• Poland
• Rest of Eastern Europe

• Asia-Pacific:
• Japan
• China
• India
• Australia & New Zealand
• ASEAN
• Rest of Asia-Pacific

• MEA:
• GCC Countries
• South Africa
• Northern Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Clinical Oncology Next Generation Sequencing (NGS) market, with a focus on this segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Russia, Germany and China in particular, will continue to achieve high revenue growth to 2029.

Leading companies and the potential for market growth
Overall world revenue for Clinical Oncology Next Generation Sequencing (NGS) will surpass $3.87 billion in 2019, our work calculates. We predict strong revenue growth through to 2029.
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Clinical Oncology Next Generation Sequencing (NGS) Market report helps you
In summary, our 253-page report provides you with the following knowledge:

• Revenue forecasts to 2029 for 4 segmentations of the Clinical Oncology Next Generation Sequencing (NGS) market, with forecasts for 4 Components, 8 Technologies, 6 Applications and 4 End Users, each forecasted at a global and regional level , discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2029 for 6 regional and 21 key national markets , See forecasts for the Clinical Oncology Next Generation Sequencing (NGS) market in North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, the UK, Italy, France, Nordic Countries, Benelux, China, India, Japan, Australia & New Zealand, ASEAN countries, GCC Countries, South Africa and Northern Africa.

• Stimulates and restrains companies and the market

• Prospects for established firms and those seeking to enter the market , including company profiles for 10 of the major companies involved in the Clinical Oncology Next Generation Sequencing (NGS) market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the Clinical Oncology Next Generation Sequencing (NGS) Sequencing market and leading companies. You will find data, trends and predictions.

Get our report today The Clinical Oncology Next Generation Sequencing (NGS) Market Forecast 2019-2029: Revenue Prospects by Component (Sequencing platform, Sequencing products, End users and Reagents, Services), by Technology (Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing (SBS), Real Time Sequencing (SMRT), Ligation Sequencing, Reversible Dye Termination Sequencing, Nano -Pore Sequencing, Others), by Application (Whole Tumor Genome Sequencing, Whole Tumor Exome Sequencing, Targeted Tumor Genome Profiling, Tumor Transcriptome Sequencing, Tumor -normal Comparisons, Others), by End user (Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories, Others) and Geography.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain

2. Clinical Oncology NGS Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Global Clinical Oncology NGS Market Size and Forecast
2.3. Market Dynamics
2.3.1. Market Drivers
2.3.2. Market Restraints
2.3.3. Market Opportunities
2.3.4. Global Clinical Oncology NGS Market: Trends
2.3.5. Mergers and Acquisitions
2.3.6. Entry of New Market Players

3. Global Clinical Oncology NGS Market Analysis and Forecast, By Component
3.1. Introduction
3.1.1. Global Clinical Oncology NGS Market, Annual Growth Rate Comparison, By Component
3.2. Global Clinical Oncology NGS Market Size and Forecast, By Component
3.2.1. Sequencing platform
3.2.2. Sequencing products
3.2.3. End users and Reagents
3.2.4. Services
3.3. Global Clinical Oncology NGS Attractiveness Index, By Component

4. Global Clinical Oncology NGS Market Analysis and Forecast, By Technology
4.1. Introduction
4.1.1. Global Clinical Oncology NGS Market, Annual Growth Rate Comparison, By Technology
4.1.2. Global Clinical Oncology NGS Market Share Comparison, By Technology (2018 & 2029)
4.2. Global Clinical Oncology NGS Market Size and Forecast, By Technology
4.2.1. Ion Semiconductor Sequencing
4.2.2. Pyro-Sequencing
4.2.3. Synthesis Sequencing (SBS)
4.2.4. Real Time Sequencing (SMRT)
4.2.5. Ligation Sequencing
4.2.6. Reversible Dye Termination Sequencing
4.2.7. Nano -Pore Sequencing
4.2.8. Others
4.3. Global Clinical Oncology NGS Attractiveness Index, By Technology

5. Global Clinical Oncology NGS Market Analysis and Forecast, By Application
5.1. Introduction
5.1.1. Global Clinical Oncology NGS Market, Annual Growth Rate Comparison, By Application
5.1.2. Global Clinical Oncology NGS Market Share Comparison, By Application (2018 & 2029)
5.2. Global Clinical Oncology NGS Market Size and Forecast, By Application
5.2.1. Whole Tumor Genome Sequencing
5.2.2. Whole Tumor Exome Sequencing
5.2.3. Targeted Tumor Genome Profiling
5.2.4. Tumor Transcriptome Sequencing
5.2.5. Tumor -normal Comparisons
5.2.6. Others
5.3. Global Clinical Oncology NGS Attractiveness Index, By Application

6. Global Clinical Oncology NGS Market Analysis and Forecast, By End user
6.1. Introduction
6.1.1. Global Clinical Oncology NGS Market, Annual Growth Rate Comparison, By End user
6.1.2. Global Clinical Oncology NGS Market Share Comparison, By End user (2018 & 2029)
6.2. Global Clinical Oncology NGS Market Size and Forecast, By End user
6.2.1. Hospital Laboratories
6.2.2. Clinical Research Organizations
6.2.3. Diagnostic Laboratories
6.2.4. Others
6.3. Global Clinical Oncology NGS Attractiveness Index, By End user

7. Global Clinical Oncology NGS Market Analysis and Forecast, By Region
7.1. Introduction
7.1.1. Global Clinical Oncology NGS Market, Annual Growth Rate Comparison, By Region
7.1.2. Global Clinical Oncology NGS Market Share Comparison, By Region (2018 & 2029)
7.2. Global Clinical Oncology NGS Market Size and Forecast, By Region
7.2.1. North America (U.S., Canada)
7.2.2. Latin America (Brazil, Mexico, Rest of Latin America)
7.2.3. Western Europe (UK, France, Germany, Italy, Spain, Nordic, Benelux, RoWE)
7.2.4. Eastern Europe (Russia, Poland, Rest of Eastern Europe)
7.2.5. Asia Pacific (Japan, China, India, ASEAN, Australia, RoAPAC)
7.2.6. MEA (GCC, South Africa, North Africa, RoMEA)
7.3. Global Clinical Oncology NGS Market Attractiveness Index, By Region

8. North America Clinical Oncology NGS Market Analysis and Forecast, 2019-2029
8.1. Introduction
8.1.1. North America Clinical Oncology NGS Market
8.1.2. North America Clinical Oncology NGS Market, Annual Growth Rate Comparison, By Country
8.2. North America Clinical Oncology NGS Market Size and Forecast, By Country
8.2.1. The U.S. Clinical Oncology NGS Market
8.2.2. Canada Clinical Oncology NGS Market
8.3. North America Clinical Oncology NGS Market Size and Forecast, By Component
8.4. North America Clinical Oncology NGS Market Size and Forecast, By Technology
8.5. North America Clinical Oncology NGS Market Size and Forecast, By Application
8.6. North America Clinical Oncology NGS Market Size and Forecast, By End user
8.7. North America Clinical Oncology NGS Market Attractiveness Index
8.8. North America Clinical Oncology NGS Market Attractiveness Index, By Country
8.9. North America Clinical Oncology NGS Market Attractiveness Index, By Component
8.10. North America Clinical Oncology NGS Market Attractiveness Index, By Technology
8.11. North America Clinical Oncology NGS Market Attractiveness Index, By Application
8.12. North America Clinical Oncology NGS Market Attractiveness Index, By End user

9. Latin America Clinical Oncology NGS Market Analysis and Forecast, 2019-2029
9.1. Introduction
9.1.1. Latin America Clinical Oncology NGS Market
9.1.2. Latin America Clinical Oncology NGS Market, Annual Growth Rate Comparison, By Country
9.2. Latin America Clinical Oncology NGS Market Size and Forecast, By Country
9.2.1. Brazil Clinical Oncology NGS Market
9.2.2. Mexico Clinical Oncology NGS Market
9.2.3. Rest of Latin America Clinical Oncology NGS Market
9.3. Latin America Clinical Oncology NGS Market Size and Forecast, By Component
9.4. Latin America Clinical Oncology NGS Market Size and Forecast, By Technology
9.5. Latin America Clinical Oncology NGS Market Size and Forecast, By Application
9.6. Latin America Clinical Oncology NGS Market Size and Forecast, By End user
9.7. Latin America Clinical Oncology NGS Market Attractiveness Index
9.8. Latin America Clinical Oncology NGS Market Attractiveness Index, By Country
9.9. Latin America Clinical Oncology NGS Market Attractiveness Index, By Component
9.10. Latin America Clinical Oncology NGS Market Attractiveness Index, By Technology
9.11. Latin America Clinical Oncology NGS Market Attractiveness Index, By Application
9.12. Latin America Clinical Oncology NGS Market Attractiveness Index, By End user

10. Western Europe Clinical Oncology NGS Market Analysis and Forecast, 2019-2029
10.1. Introduction
10.1.1. Western Europe Clinical Oncology NGS Market
10.1.2. Western Europe Clinical Oncology NGS Market, Annual Growth Rate Comparison, By Country
10.2. Western Europe Clinical Oncology NGS Market Size and Forecast, By Country
10.2.1. U.K. Clinical Oncology NGS Market
10.2.2. France Clinical Oncology NGS Market
10.2.3. Germany Clinical Oncology NGS Market
10.2.4. Italy Clinical Oncology NGS Market
10.2.5. Spain Clinical Oncology NGS Market
10.2.6. Nordic Clinical Oncology NGS Market
10.2.7. Benelux Clinical Oncology NGS Market
10.2.8. Rest of Western Europe Clinical Oncology NGS Market
10.3. Western Europe Clinical Oncology NGS Market Size and Forecast, By Component
10.4. Western Europe Clinical Oncology NGS Market Size and Forecast, By Technology
10.5. Western Europe Clinical Oncology NGS Market Size and Forecast, By Application
10.6. Western Europe Clinical Oncology NGS Market Size and Forecast, By End user
10.7. Western Europe Clinical Oncology NGS Market Attractiveness Index
10.8. Western Europe Clinical Oncology NGS Market Attractiveness Index, By Country
10.9. Western Europe Clinical Oncology NGS Market Attractiveness Index, By Component
10.10. Western Europe Clinical Oncology NGS Market Attractiveness Index, By Technology
10.11. Western Europe Clinical Oncology NGS Market Attractiveness Index, By Application
10.12. Western Europe Clinical Oncology NGS Market Attractiveness Index, By End user

11. Eastern Europe Clinical Oncology NGS Market Analysis and Forecast, 2019-2029
11.1. Introduction
11.1.1. Eastern Europe Clinical Oncology NGS Market
11.1.2. Eastern Europe Clinical Oncology NGS Market, Annual Growth Rate Comparison, By Country
11.2. Eastern Europe Clinical Oncology NGS Market Size and Forecast, By Country
11.2.1. Russia Clinical Oncology NGS Market
11.2.2. Poland Clinical Oncology NGS Market
11.2.3. Rest of Eastern Europe Clinical Oncology NGS Market
11.3. Eastern Europe Clinical Oncology NGS Market Size and Forecast, By Component
11.4. Eastern Europe Clinical Oncology NGS Market Size and Forecast, By Technology
11.5. Eastern Europe Clinical Oncology NGS Market Size and Forecast, By Application
11.6. Eastern Europe Clinical Oncology NGS Market Size and Forecast, By End user
11.7. Eastern Europe Clinical Oncology NGS Market Attractiveness Index
11.8. Eastern Europe Clinical Oncology NGS Market Attractiveness Index, By Country
11.9. Eastern Europe Clinical Oncology NGS Market Attractiveness Index, By Component
11.10. Eastern Europe Clinical Oncology NGS Market Attractiveness Index, By Technology
11.11. Eastern Europe Clinical Oncology NGS Market Attractiveness Index, By Application
11.12. Eastern Europe Clinical Oncology NGS Market Attractiveness Index, By End user

12. Asia Pacific Clinical Oncology NGS Market Analysis and Forecast, 2019-2029
12.1. Introduction
12.1.1. Asia Pacific Clinical Oncology NGS Market
12.1.2. Asia Pacific Clinical Oncology NGS Market, Annual Growth Rate Comparison, By Country
12.2. Asia Pacific Clinical Oncology NGS Market Size and Forecast, By Country
12.2.1. China Clinical Oncology NGS Market
12.2.2. India Clinical Oncology NGS Market
12.2.3. Australia Clinical Oncology NGS Market
12.2.4. ASEAN Clinical Oncology NGS Market
12.2.5. Japan Clinical Oncology NGS Market
12.2.6. Rest of Asia Pacific Clinical Oncology NGS Market
12.3. Asia Pacific Clinical Oncology NGS Market Size and Forecast, By Component
12.4. Asia Pacific Clinical Oncology NGS Market Size and Forecast, By Technology
12.5. Asia Pacific Clinical Oncology NGS Market Size and Forecast, By Application
12.6. Asia Pacific Clinical Oncology NGS Market Size and Forecast, By End user
12.7. Asia Pacific Clinical Oncology NGS Market Attractiveness Index
12.8. Asia Pacific Clinical Oncology NGS Market Attractiveness Index, By Country
12.9. Asia Pacific Clinical Oncology NGS Market Attractiveness Index, By Component
12.10. Asia Pacific Clinical Oncology NGS Market Attractiveness Index, By Technology
12.11. Asia Pacific Clinical Oncology NGS Market Attractiveness Index, By Application
12.12. Asia Pacific Clinical Oncology NGS Market Attractiveness Index, By End user

13. MEA Clinical Oncology NGS Market Analysis and Forecast, 2019-2029
13.1. Introduction
13.1.1. MEA Clinical Oncology NGS Market
13.1.2. MEA Clinical Oncology NGS Market, Annual Growth Rate Comparison, By Country
13.2. MEA Clinical Oncology NGS Market Size and Forecast, By Country
13.2.1. GCC Clinical Oncology NGS Market
13.2.2. South Africa Clinical Oncology NGS Market
13.2.3. North Africa Clinical Oncology NGS Market
13.2.4. Rest of MEA Clinical Oncology NGS Market
13.3. MEA Clinical Oncology NGS Market Size and Forecast, By Component
13.4. MEA Clinical Oncology NGS Market Size and Forecast, By Technology
13.5. MEA Clinical Oncology NGS Market Size and Forecast, By Application
13.6. MEA Clinical Oncology NGS Market Size and Forecast, By End user
13.7. MEA Clinical Oncology NGS Market Attractiveness Index
13.8. MEA Clinical Oncology NGS Market Attractiveness Index, By Country
13.9. MEA Clinical Oncology NGS Market Attractiveness Index, By Component
13.10. MEA Clinical Oncology NGS Market Attractiveness Index, By Technology
13.11. MEA Clinical Oncology NGS Market Attractiveness Index, By Application
13.12. MEA Clinical Oncology NGS Market Attractiveness Index, By End user

14. Leading Companies in the Clinical Oncology NGS Market
14.1. Competition Dashboard
14.2. Company Share Analysis
14.3. Company Profiling of 25 Major Players
14.3.1. Company Overview
14.3.2. Component Offerings
14.3.3. Financial Performance (2016-2018)
14.3.4. Recent Initiatives
14.3.5. Average Gross Margin (2016-2018)

15. Conclusion

16. Glossary

List of Figures
17.1. Research design
17.2. Market segmentation & scope
17.3. Value chain analysis
17.4. Porter's Five Forces
17.5. Market summary
17.6. Market driver analysis (Current & Future Impact)
17.7. Market restraint analysis (Current & Future Impact)
17.8. Global Clinical Oncology NGS Market by Component, 2019-2029 (USD million)
17.9. Global Clinical Oncology NGS Market for Sequencing platform, 2019-2029 (USD million)
17.10. Global Clinical Oncology NGS Market for Sequencing products, 2019-2029 (USD million)
17.11. Global Clinical Oncology NGS Market for Kits and Reagents, 2019-2029 (USD million)
17.12. Global Clinical Oncology NGS Market for Services, 2019-2029 (USD million)
17.13. Global Clinical Oncology NGS Market by Technology, 2019-2029 (USD million)
17.14. Global Clinical Oncology NGS Market for Ion Semiconductor Sequencing, 2019-2029 (USD million)
17.15. Global Clinical Oncology NGS Market for Pyro-Sequencing, 2019-2029 (USD million)
17.16. Global Clinical Oncology NGS Market for SBS, 2019-2029 (USD million)
17.17. Global Clinical Oncology NGS Market for SMRT, 2019-2029 (USD million)
17.18. Global Clinical Oncology NGS Market for Ligation Sequencing, 2019-2029 (USD million)
17.19. Global Clinical Oncology NGS Market for Reversible Dye Termination Sequencing, 2019-2029 (USD million)
17.20. Global Clinical Oncology NGS Market for Nano -Pore Sequencing, 2019-2029 (USD million)
17.21. Global Clinical Oncology NGS Market for Other technology, 2019-2029 (USD million)
17.22. Global Clinical Oncology NGS Market by Application, 2019-2029 (USD million)
17.23. Global Clinical Oncology NGS Market for Whole Tumor Genome Sequencing, 2019- 2029 (USD million)
17.24. Global Clinical Oncology NGS Market for Whole Tumor Exome Sequencing, 2019-2029 (USD million)
17.25. Global Clinical Oncology NGS Market for Targeted Tumor Genome Profiling, 2019-2029 (USD million)
17.26. Global Clinical Oncology NGS Market for Tumor Transcriptome Sequencing, 2019-2029 (USD million)
17.27. Global Clinical Oncology NGS Market for Tumor -normal Comparisons, 2019-2029 (USD million)
17.28. Global Clinical Oncology NGS Market for Others, 2019-2029 (USD million)
17.29. Global Clinical Oncology NGS Market by End user, 2019-2029 (USD million)
17.30. Global Clinical Oncology NGS Market for Hospital Laboratories, 2019 - 2029 (USD million)
17.31. Global Clinical Oncology NGS Market for Clinical Research Organizations, 2019-2029 (USD million)
17.32. Global Clinical Oncology NGS Market for Diagnostic Laboratories, 2019-2029 (USD million)
17.33. Global Clinical Oncology NGS Market for Other End users, 2019-2029 (USD million)
17.34. North America Clinical Oncology NGS Market by Component, 2019-2029 (USD million)
17.35. North America Clinical Oncology NGS Market for Sequencing platform, 2019-2029 (USD million)
17.36. North America Clinical Oncology NGS Market for Sequencing products, 2019- 2029 (USD million)
17.37. North America Clinical Oncology NGS Market for kits and reagents, 2019- 2029 (USD million)
17.38. North America Clinical Oncology NGS Market for services, 2019- 2029 (USD million)
17.39. North America Clinical Oncology NGS Market by Technology, 2019- 2029 (USD million)
17.40. North America Clinical Oncology NGS Market for Ion Semiconductor Sequencing, 2019- 2029 (USD million)
17.41. North America Clinical Oncology NGS Market for Pyro-Sequencing, 2019- 2029 (USD million)
17.42. North America Clinical Oncology NGS Market for SBS, 2019-2029 (USD million)
17.43. North America Clinical Oncology NGS Market for SMRT, 2019-2029 (USD million)
17.44. North America Clinical Oncology NGS Market for Ligation Sequencing, 2019-2029 (USD million)
17.45. North America Clinical Oncology NGS Market for Reversible Dye Termination Sequencing, 2019-2029 (USD million)
17.46. North America Clinical Oncology NGS Market for Nano -Pore Sequencing, 2019-2029 (USD million)
17.47. North America Clinical Oncology NGS Market for others, 2019-2029 (USD million)
17.48. North America Clinical Oncology NGS Market by Application, 2019- 2029 (USD million)
17.49. North America Clinical Oncology NGS Market for Whole Tumor Genome Sequencing, 2019-2029 (USD million)
17.50. North America Clinical Oncology NGS Market for Whole Tumor Exome Sequencing, 2019-2029 (USD million)
17.51. North America Clinical Oncology NGS Market for Targeted Tumor Genome Profiling, 2019- 2029 (USD million)
17.52. North America Clinical Oncology NGS Market for Tumor Transcriptome Sequencing, 2019- 2029 (USD million)
17.53. North America Clinical Oncology NGS Market for Tumor -normal Comparisons, 2019- 2029 (USD million)
17.54. North America Clinical Oncology NGS Market for Others, 2019-2029 (USD million)
17.55. North America Clinical Oncology NGS Market by End user, 2019-2029 (USD million)
17.56. North America Clinical Oncology NGS Market for Hospital Laboratories, 2019-2029 (USD million)
17.57. North America Clinical Oncology NGS Market for Clinical Research Organizations, 2019-2029 (USD million)
17.58. North America Clinical Oncology NGS Market for Diagnostic Laboratories, 2019-2029 (USD million)
17.59. North America Clinical Oncology NGS Market for other end users, 2019-2029 (USD million)
17.60. Latin America Clinical Oncology NGS Market by Component, 2019-2029 (USD million)
17.61. Latin America Clinical Oncology NGS Market for Sequencing platform, 2019-2029 (USD million)
17.62. Latin America Clinical Oncology NGS Market for Sequencing products, 2019- 2029 (USD million)
17.63. Latin America Clinical Oncology NGS Market for kits and reagents, 2019- 2029 (USD million)
17.64. Latin America Clinical Oncology NGS Market for services, 2019- 2029 (USD million)
17.65. Latin America Clinical Oncology NGS Market by Technology, 2019- 2029 (USD million)
17.66. Latin America Clinical Oncology NGS Market for Ion Semiconductor Sequencing, 2019- 2029 (USD million)
17.67. Latin America Clinical Oncology NGS Market for Pyro-Sequencing, 2019- 2029 (USD million)
17.68. Latin America Clinical Oncology NGS Market for SBS, 2019-2029 (USD million)
17.69. Latin America Clinical Oncology NGS Market for SMRT, 2019-2029 (USD million)
17.70. Latin America Clinical Oncology NGS Market for Ligation Sequencing, 2019-2029 (USD million)
17.71. Latin America Clinical Oncology NGS Market for Reversible Dye Termination Sequencing, 2019-2029 (USD million)
17.72. Latin America Clinical Oncology NGS Market for Nano -Pore Sequencing, 2019-2029 (USD million)
17.73. Latin America Clinical Oncology NGS Market for others, 2019-2029 (USD million)
17.74. Latin America Clinical Oncology NGS Market by Application, 2019- 2029 (USD million)
17.75. Latin America Clinical Oncology NGS Market for Whole Tumor Genome Sequencing, 2019-2029 (USD million)
17.76. Latin America Clinical Oncology NGS Market for Whole Tumor Exome Sequencing, 2019-2029 (USD million)
17.77. Latin America Clinical Oncology NGS Market for Targeted Tumor Genome Profiling, 2019- 2029 (USD million)
17.78. Latin America Clinical Oncology NGS Market for Tumor Transcriptome Sequencing, 2019- 2029 (USD million)
17.79. Latin America Clinical Oncology NGS Market for Tumor -normal Comparisons, 2019- 2029 (USD million)
17.80. Latin America Clinical Oncology NGS Market for Others, 2019-2029 (USD million)
17.81. Latin America Clinical Oncology NGS Market by End user, 2019-2029 (USD million)
17.82. Latin America Clinical Oncology NGS Market for Hospital Laboratories, 2019-2029 (USD million)
17.83. Latin America Clinical Oncology NGS Market for Clinical Research Organizations, 2019-2029 (USD million)
17.84. Latin America Clinical Oncology NGS Market for Diagnostic Laboratories, 2019-2029 (USD million)
17.85. Latin America Clinical Oncology NGS Market for other end users, 2019-2029 (USD million)
17.86. Western Europe America Clinical Oncology NGS Market by Component, 2019-2029 (USD million)
17.87. Western Europe America Clinical Oncology NGS Market for Sequencing platform, 2019-2029 (USD million)
17.88. Western Europe America Clinical Oncology NGS Market for Sequencing products, 2019- 2029 (USD million)
17.89. Western Europe America Clinical Oncology NGS Market for kits and reagents, 2019- 2029 (USD million)
17.90. Western Europe America Clinical Oncology NGS Market for services, 2019- 2029 (USD million)
17.91. Western Europe America Clinical Oncology NGS Market by Technology, 2019- 2029 (USD million)
17.92. Western Europe America Clinical Oncology NGS Market for Ion Semiconductor Sequencing, 2019- 2029 (USD million)
17.93. Western Europe America Clinical Oncology NGS Market for Pyro-Sequencing, 2019- 2029 (USD million)
17.94. Western Europe America Clinical Oncology NGS Market for SBS, 2019-2029 (USD million)
17.95. Western Europe America Clinical Oncology NGS Market for SMRT, 2019-2029 (USD million)
17.96. Western Europe America Clinical Oncology NGS Market for Ligation Sequencing, 2019-2029 (USD million)
17.97. Western Europe America Clinical Oncology NGS Market for Reversible Dye Termination Sequencing, 2019-2029 (USD million)
17.98. Western Europe America Clinical Oncology NGS Market for Nano -Pore Sequencing, 2019-2029 (USD million)
17.99. Western Europe America Clinical Oncology NGS Market for others, 2019-2029 (USD million)
17.100. Western Europe America Clinical Oncology NGS Market by Application, 2019- 2029 (USD million)
17.101. Western Europe America Clinical Oncology NGS Market for Whole Tumor Genome Sequencing, 2019-2029 (USD million)
17.102. Western Europe America Clinical Oncology NGS Market for Whole Tumor Exome Sequencing, 2019-2029 (USD million)
17.103. Western Europe America Clinical Oncology NGS Market for Targeted Tumor Genome Profiling, 2019- 2029 (USD million)
17.104. Western Europe America Clinical Oncology NGS Market for Tumor Transcriptome Sequencing, 2019- 2029 (USD million)
17.105. Western Europe America Clinical Oncology NGS Market for Tumor -normal Comparisons, 2019- 2029 (USD million)
17.106. Western Europe America Clinical Oncology NGS Market for Others, 2019-2029 (USD million)
17.107. Western Europe America Clinical Oncology NGS Market by End user, 2019-2029 (USD million)
17.108. Western Europe America Clinical Oncology NGS Market for Hospital Laboratories, 2019-2029 (USD million)
17.109. Western Europe America Clinical Oncology NGS Market for Clinical Research Organizations, 2019-2029 (USD million)
17.110. Western Europe America Clinical Oncology NGS Market for Diagnostic Laboratories, 2019-2029 (USD million)
17.111. Western Europe America Clinical Oncology NGS Market for other end users, 2019-2029 (USD million)
17.112. Eastern Europe America Clinical Oncology NGS Market by Component, 2019-2029 (USD million)
17.113. Eastern Europe America Clinical Oncology NGS Market for Sequencing platform, 2019-2029 (USD million)
17.114. Eastern Europe America Clinical Oncology NGS Market for Sequencing products, 2019- 2029 (USD million)
17.115. Eastern Europe America Clinical Oncology NGS Market for kits and reagents, 2019- 2029 (USD million)
17.116. Eastern Europe America Clinical Oncology NGS Market for services, 2019- 2029 (USD million)
17.117. Eastern Europe America Clinical Oncology NGS Market by Technology, 2019- 2029 (USD million)
17.118. Eastern Europe America Clinical Oncology NGS Market for Ion Semiconductor Sequencing, 2019- 2029 (USD million)
17.119. Eastern Europe America Clinical Oncology NGS Market for Pyro-Sequencing, 2019- 2029 (USD million)
17.120. Eastern Europe America Clinical Oncology NGS Market for SBS, 2019-2029 (USD million)
17.121. Eastern Europe America Clinical Oncology NGS Market for SMRT, 2019-2029 (USD million)
17.122. Eastern Europe America Clinical Oncology NGS Market for Ligation Sequencing, 2019-2029 (USD million)
17.123. Eastern Europe America Clinical Oncology NGS Market for Reversible Dye Termination Sequencing, 2019-2029 (USD million)
17.124. Eastern Europe America Clinical Oncology NGS Market for Nano -Pore Sequencing, 2019-2029 (USD million)
17.125. Eastern Europe America Clinical Oncology NGS Market for others, 2019-2029 (USD million)
17.126. Eastern Europe America Clinical Oncology NGS Market by Application, 2019- 2029 (USD million)
17.127. Eastern Europe America Clinical Oncology NGS Market for Whole Tumor Genome Sequencing, 2019-2029 (USD million)
17.128. Eastern Europe America Clinical Oncology NGS Market for Whole Tumor Exome Sequencing, 2019-2029 (USD million)
17.129. Eastern Europe America Clinical Oncology NGS Market for Targeted Tumor Genome Profiling, 2019- 2029 (USD million)
17.130. Eastern Europe America Clinical Oncology NGS Market for Tumor Transcriptome Sequencing, 2019- 2029 (USD million)
17.131. Eastern Europe America Clinical Oncology NGS Market for Tumor -normal Comparisons, 2019- 2029 (USD million)
17.132. Eastern Europe America Clinical Oncology NGS Market for Others, 2019-2029 (USD million)
17.133. Eastern Europe America Clinical Oncology NGS Market by End user, 2019-2029 (USD million)
17.134. Eastern Europe America Clinical Oncology NGS Market for Hospital Laboratories, 2019-2029 (USD million)
17.135. Eastern Europe America Clinical Oncology NGS Market for Clinical Research Organizations, 2019-2029 (USD million)
17.136. Eastern Europe America Clinical Oncology NGS Market for Diagnostic Laboratories, 2019-2029 (USD million)
17.137. Eastern Europe America Clinical Oncology NGS Market for other end users, 2019-2029 (USD million)
17.138. Asia Pacific America Clinical Oncology NGS Market by Component, 2019-2029 (USD million)
17.139. Asia Pacific America Clinical Oncology NGS Market for Sequencing platform, 2019-2029 (USD million)
17.140. Asia Pacific America Clinical Oncology NGS Market for Sequencing products, 2019- 2029 (USD million)
17.141. Asia Pacific America Clinical Oncology NGS Market for kits and reagents, 2019- 2029 (USD million)
17.142. Asia Pacific America Clinical Oncology NGS Market for services, 2019- 2029 (USD million)
17.143. Asia Pacific America Clinical Oncology NGS Market by Technology, 2019- 2029 (USD million)
17.144. Asia Pacific America Clinical Oncology NGS Market for Ion Semiconductor Sequencing, 2019- 2029 (USD million)
17.145. Asia Pacific America Clinical Oncology NGS Market for Pyro-Sequencing, 2019- 2029 (USD million)
17.146. Asia Pacific America Clinical Oncology NGS Market for SBS, 2019-2029 (USD million)
17.147. Asia Pacific America Clinical Oncology NGS Market for SMRT, 2019-2029 (USD million)
17.148. Asia Pacific America Clinical Oncology NGS Market for Ligation Sequencing, 2019-2029 (USD million)
17.149. Asia Pacific America Clinical Oncology NGS Market for Reversible Dye Termination Sequencing, 2019-2029 (USD million)
17.150. Asia Pacific America Clinical Oncology NGS Market for Nano -Pore Sequencing, 2019-2029 (USD million)
17.151. Asia Pacific America Clinical Oncology NGS Market for others, 2019-2029 (USD million)
17.152. Asia Pacific America Clinical Oncology NGS Market by Application, 2019- 2029 (USD million)
17.153. Asia Pacific America Clinical Oncology NGS Market for Whole Tumor Genome Sequencing, 2019-2029 (USD million)
17.154. Asia Pacific America Clinical Oncology NGS Market for Whole Tumor Exome Sequencing, 2019-2029 (USD million)
17.155. Asia Pacific America Clinical Oncology NGS Market for Targeted Tumor Genome Profiling, 2019- 2029 (USD million)
17.156. Asia Pacific America Clinical Oncology NGS Market for Tumor Transcriptome Sequencing, 2019- 2029 (USD million)
17.157. Asia Pacific America Clinical Oncology NGS Market for Tumor -normal Comparisons, 2019- 2029 (USD million)
17.158. Asia Pacific America Clinical Oncology NGS Market for Others, 2019-2029 (USD million)
17.159. Asia Pacific America Clinical Oncology NGS Market by End user, 2019-2029 (USD million)
17.160. Asia Pacific America Clinical Oncology NGS Market for Hospital Laboratories, 2019-2029 (USD million)
17.161. Asia Pacific America Clinical Oncology NGS Market for Clinical Research Organizations, 2019-2029 (USD million)
17.162. Asia Pacific America Clinical Oncology NGS Market for Diagnostic Laboratories, 2019-2029 (USD million)
17.163. Asia Pacific America Clinical Oncology NGS Market for other end users, 2019-2029 (USD million)
17.164. MEA America Clinical Oncology NGS Market by Component, 2019-2029 (USD million)
17.165. MEA America Clinical Oncology NGS Market for Sequencing platform, 2019-2029 (USD million)
17.166. MEA America Clinical Oncology NGS Market for Sequencing products, 2019- 2029 (USD million)
17.167. MEA America Clinical Oncology NGS Market for kits and reagents, 2019- 2029 (USD million)
17.168. MEA America Clinical Oncology NGS Market for services, 2019- 2029 (USD million)
17.169. MEA America Clinical Oncology NGS Market by Technology, 2019- 2029 (USD million)
17.170. MEA America Clinical Oncology NGS Market for Ion Semiconductor Sequencing, 2019- 2029 (USD million)
17.171. MEA America Clinical Oncology NGS Market for Pyro-Sequencing, 2019- 2029 (USD million)
17.172. MEA America Clinical Oncology NGS Market for SBS, 2019-2029 (USD million)
17.173. MEA America Clinical Oncology NGS Market for SMRT, 2019-2029 (USD million)
17.174. MEA America Clinical Oncology NGS Market for Ligation Sequencing, 2019-2029 (USD million)
17.175. MEA America Clinical Oncology NGS Market for Reversible Dye Termination Sequencing, 2019-2029 (USD million)
17.176. MEA America Clinical Oncology NGS Market for Nano -Pore Sequencing, 2019-2029 (USD million)
17.177. MEA America Clinical Oncology NGS Market for others, 2019-2029 (USD million)
17.178. MEA America Clinical Oncology NGS Market by Application, 2019-2029 (USD million)
17.179. MEA America Clinical Oncology NGS Market for Whole Tumor Genome Sequencing, 2019-2029 (USD million)
17.180. MEA America Clinical Oncology NGS Market for Whole Tumor Exome Sequencing, 2019-2029 (USD million)
17.181. MEA America Clinical Oncology NGS Market for Targeted Tumor Genome Profiling, 2019- 2029 (USD million)
17.182. MEA America Clinical Oncology NGS Market for Tumor Transcriptome Sequencing, 2019- 2029 (USD million)
17.183. MEA America Clinical Oncology NGS Market for Tumor -normal Comparisons, 2019- 2029 (USD million)
17.184. MEA America Clinical Oncology NGS Market for Others, 2019-2029 (USD million)
17.185. MEA America Clinical Oncology NGS Market by End user, 2019-2029 (USD million)
17.186. MEA America Clinical Oncology NGS Market for Hospital Laboratories, 2019-2029 (USD million)
17.187. MEA America Clinical Oncology NGS Market for Clinical Research Organizations, 2019-2029 (USD million)
17.188. MEA America Clinical Oncology NGS Market for Diagnostic Laboratories, 2019-2029 (USD million)
17.189. MEA America Clinical Oncology NGS Market for other end users, 2019-2029 (USD million)
17.190. List of Companies

List of Tables
18.1. Global Clinical Oncology NGS Market, by Component, 2019-2029 (USD million)
18.2. Global Clinical Oncology NGS Market, by Technology, 2019-2029 (USD million)
18.3. Global Clinical Oncology NGS Market, by Application, 2019-2029 (USD million)
18.4. Global Clinical Oncology NGS Market, by End user, 2019-2029 (USD million)
18.5. North America Clinical Oncology NGS Market, 2019-2029 (USD million)
18.6. U.S. Clinical Oncology NGS Market, 2019-2029 (USD million)
18.7. Canada Clinical Oncology NGS Market, 2019-2029 (USD million)
18.8. Latin America Clinical Oncology NGS Market, 2019-2029 (USD million)
18.9. Brazil Clinical Oncology NGS Market, 2019-2029 (USD million)
18.10. Mexico Clinical Oncology NGS Market, 2019-2029 (USD million)
18.11. Rest of Latin America Clinical Oncology NGS Market, 2019-2029 (USD million)
18.12. Western Europe Clinical Oncology NGS Market, 2019-2029 (USD million)
18.13. UK Clinical Oncology NGS Market, 2019-2029 (USD million)
18.14. France Clinical Oncology NGS Market, 2019-2029 (USD million)
18.15. Germany Clinical Oncology NGS Market, 2019-2029 (USD million)
18.16. Italy Clinical Oncology NGS Market, 2019-2029 (USD million)
18.17. Nordic Clinical Oncology NGS Market, 2019-2029 (USD million)
18.18. Benelux Clinical Oncology NGS Market, 2019-2029 (USD million)
18.19. Rest of Western Europe Clinical Oncology NGS Market, 2019-2029 (USD million)
18.20. Eastern Europe Clinical Oncology NGS Market, 2019-2029 (USD million)
18.21. Russia Clinical Oncology NGS Market, 2019-2029 (USD million)
18.22. Poland Clinical Oncology NGS Market, 2019-2029 (USD million)
18.23. Rest of Eastern Europe Clinical Oncology NGS Market, 2019-2029 (USD million)
18.24. Asia Pacific Clinical Oncology NGS Market, 2019-2029 (USD million)
18.25. Japan Clinical Oncology NGS Market, 2019-2029 (USD million)
18.26. India Clinical Oncology NGS Market, 2019-2029 (USD million)
18.27. Australia Clinical Oncology NGS Market, 2019-2029 (USD million)
18.28. ASEAN Clinical Oncology NGS Market, 2019-2029 (USD million)
18.29. China Clinical Oncology NGS Market, 2019-2029 (USD million)
18.30. Rest of Asia Pacific Clinical Oncology NGS Market, 2019-2029 (USD million)
18.31. MEA Clinical Oncology NGS Market, 2019-2029 (USD million)
18.32. South Africa Clinical Oncology NGS Market, 2019-2029 (USD million)
18.33. North Africa Clinical Oncology NGS Market, 2019-2029 (USD million)
18.34. GCC Clinical Oncology NGS Market, 2019-2029 (USD million)
18.35. Rest of MEA Clinical Oncology NGS Market, 2019-2029 (USD million)

Agilent Technologies
Amoy Diagnostics
BGI (Beijing Genomics Institute)
Biomatters Ltd.
Bio-Rad Laboratories, Inc.
Cancer Genetics Inc
Caris Life Sciences
DNASTAR Inc.
Exosome Diagnostics
Foundation Medicine
GATC Biotech Ag
Genomatix Software GmbH
GnuBIO
Illumina, Inc.
Knome Inc.
Life technologies Corp.
Macrogen Inc.
Myriad Genetics
Oxford Nanopore Technologies Ltd
Pacific Bioscience, Inc.
Paradigm Diagnostics, Inc
Partek, Inc.
Perkin Elmer, Inc.
Qiagen NV
Roche sequencing (454 Life Sciences)
Vela Diagnostics